A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts).
Shubham Pant(The University of Texas MD Anderson Cancer Center), Manish R. Patel(Sarah Cannon), William T. McMillen(Eli Lilly (United States)), Johanna C. Bendell(Dana-Farber Cancer Institute), Gu Mi(Eli Lilly (United States)), Geoffrey I. Shapiro(Brigham and Women's Hospital), Eunice Yuen(Eli Lilly (United Kingdom)), Michael Millward(The University of Western Australia), Melinda D. Willard, Sajan Joseph(Eli Lilly (United States)), Dan Wang(Tianjin University of Traditional Chinese Medicine), Shripad V. Bhagwat(Eli Lilly (United States)), Ramón V. Tiu(Eli Lilly (United States)), Ryan J. Sullivan(Dana-Farber Cancer Institute)
Cited by 24
Related Papers
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
|Cell|2018|2k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k